APA (7th ed.) Citation

Peck-Radosavljevic, M., Boletis, J., Besisik, F., Lucia Ferra, M., Alric, L., Samuel, D., . . . Cheinquer, H. (2007). [628] USE OF LOW-DOSE PEGINTERFERON a-2a (40 kD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: INTERIM RESULTS FROM A RANDOMISED STUDY. Journal of Hepatology, 46, S237. https://doi.org/10.1016/S0168-8278(07)62226-0

Chicago Style (17th ed.) Citation

Peck-Radosavljevic, M., J. Boletis, F. Besisik, M. Lucia Ferra, L. Alric, D. Samuel, D. Messinger, H. Junker, and H. Cheinquer. "[628] USE OF LOW-DOSE PEGINTERFERON A-2a (40 KD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: INTERIM RESULTS FROM A RANDOMISED STUDY." Journal of Hepatology 46 (2007): S237. https://doi.org/10.1016/S0168-8278(07)62226-0.

MLA (9th ed.) Citation

Peck-Radosavljevic, M., et al. "[628] USE OF LOW-DOSE PEGINTERFERON A-2a (40 KD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: INTERIM RESULTS FROM A RANDOMISED STUDY." Journal of Hepatology, vol. 46, 2007, p. S237, https://doi.org/10.1016/S0168-8278(07)62226-0.